S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   443.97 (-0.19%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   443.97 (-0.19%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   443.97 (-0.19%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   443.97 (-0.19%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:CFRX

ContraFect (CFRX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.05
$0.06
50-Day Range
$0.05
$0.07
52-Week Range
$0.04
$13.02
Volume
910,200 shs
Average Volume
1.39 million shs
Market Capitalization
$535,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

ContraFect MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
5,900.0% Upside
$3.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.44) to ($1.50) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.77 out of 5 stars

CFRX stock logo

About ContraFect Stock (NASDAQ:CFRX)

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.

CFRX Stock News Headlines

ContraFect Corp CFRXQ
ContraFect Corp CFRX
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
ContraFect: Q3 Earnings Snapshot
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
CFRX: IND Application for CF-370 Submitted to FDA…
CFRX: CF-370 IND to be Filed in 3Q23…
ContraFect (CFRX) Receives a Buy from Maxim Group
ContraFect: Q2 Earnings Snapshot
ContraFect Corp
8-K: CONTRAFECT Corp
See More Headlines
Receive CFRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ContraFect and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CFRX
Fax
N/A
Employees
23
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.00
High Stock Price Target
$3.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+5,900.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-65,150,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($19.92) per share

Miscellaneous

Free Float
10,639,000
Market Cap
$535,000.00
Optionable
Not Optionable
Beta
0.29
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Roger James Pomerantz FACP (Age 66)
    M.D., Chairman, CEO & President
    Comp: $970.72k
  • Mr. Michael Messinger CPA (Age 48)
    Chief Financial Officer
    Comp: $543.14k
  • Ms. Natalie Bogdanos J.D. (Age 54)
    General Counsel, Corporate Secretary & Data Protection Officer
    Comp: $531.2k
  • Mr. Matthew Salamone P.H.R.
    SPHR, Vice President of Human Resources
  • Dr. Gary Woodnutt (Age 66)
    Senior Vice President of Translational Sciences & Preclinical Development
  • Dr. William Garrett Nichols M.D. (Age 54)
    M.S., Interim Chief Medical Officer

CFRX Stock Analysis - Frequently Asked Questions

Should I buy or sell ContraFect stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CFRX shares.
View CFRX analyst ratings
or view top-rated stocks.

What is ContraFect's stock price target for 2024?

1 brokers have issued 1-year price targets for ContraFect's stock. Their CFRX share price targets range from $3.00 to $3.00. On average, they expect the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 5,900.0% from the stock's current price.
View analysts price targets for CFRX
or view top-rated stocks among Wall Street analysts.

How were ContraFect's earnings last quarter?

ContraFect Co. (NASDAQ:CFRX) announced its earnings results on Monday, November, 15th. The biotechnology company reported ($10.40) earnings per share for the quarter, beating analysts' consensus estimates of ($22.64) by $12.24.

When did ContraFect's stock split?

ContraFect shares reverse split on the morning of Tuesday, February 14th 2023. The 1-80 reverse split was announced on Tuesday, February 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What other stocks do shareholders of ContraFect own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ContraFect investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Verastem (VSTM), Vaxart (VXRT), Matinas BioPharma (MTNB), VBI Vaccines (VBIV), Novavax (NVAX), Cidara Therapeutics (CDTX), Gilead Sciences (GILD) and Dynavax Technologies (DVAX).

Who are ContraFect's major shareholders?

ContraFect's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

This page (NASDAQ:CFRX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners